J&J submitted a New Drug Application to the FDA for TAR-200 in January 2025 following positive data from the SunRISe-1 trial.

The US FDA has cleared BlackfinBio's application for a Phase I/II trial of BFB-101, an AAV gene therapy designed to treat ...

Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...